Manal Hamdy El-Sayed

Manal Hamdy El-Sayed

Auto-generated profile, based on publicly available information

Manal Hamdy El-Sayed

Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
IWImam Waked
Imam Waked
GEGamal Esmat
Gamal Esmat
AEAisha Elsharkawy
Aisha Elsharkawy
MEMagdy El-Serafy
Magdy El-Serafy
WAWael Abdel-Razek
Wael Abdel-Razek
HZHala Zaid
Hala Zaid

23 July 2020 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
ACAndrea L. Cox
Andrea L. Cox
MEManal H. El-Sayed
Manal H. El-Sayed
JKJia-Horng Kao
Jia-Horng Kao
JLJeffrey Lazarus
Jeffrey Lazarus
MLMaud Lemoine
Maud Lemoine
Fabien ZoulimFabien Zoulim
Fabien Zoulim

25 January 2021 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
HDHany M. Dabbous
Hany M. Dabbous
SASherief Abd-Elsalam
Sherief Abd-Elsalam
MEManal H. El-Sayed
Manal H. El-Sayed
ASAhmed F Sherief
Ahmed F Sherief
FEFatma F. S. Ebeid
Fatma F. S. Ebeid
MTMohamed Awad Tageldin
Mohamed Awad Tageldin

1 May 2023 in Hepatology
Verified
Journal Article
Open access
JHJessica Howell
Jessica Howell
CSChris Seaman
Chris Seaman
JWJack Wallace
Jack Wallace
YXYinzong Xiao
Yinzong Xiao
NSNick Scott
Nick Scott
MHMargaret E. Hellard
Margaret E. Hellard
Hepatitis B (HBV) is a major cause of global morbidity and mortality, and the leading cause of liver cancer worldwide. Significant advances have recently been made toward the development of a finite HBV treatment that achieves permanent loss of HBsAg and HBV DNA (so-called “HBV cure”), which could provide the means to eliminate HBV as a public health threat. However, the HBV cure is just one step toward achieving WHO HBV elimination targets by 2030, and much work must be done now to prepare for the successful implementation of the HBV cure. In this review, we describe the required steps to rapidly scale-up future HBV cure equitably. We present key actions required for successful HBV cure implementation, integrated within the World Health Organization (WHO) Global Health Sector Strategy (GHSS) 2022–2030 framework. Finally, we highlight what can be done now to progress toward the 2030 HBV elimination targets using available tools to ensure that we are preparing, but not waiting, for the cure.

20 December 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
RERasha Eletreby
Rasha Eletreby
MEMagdy El‐Serafy
Magdy El‐Serafy
MAMahmoud Anees
Mahmoud Anees
GKGamal Kasem
Gamal Kasem
MSMarwa Salama
Marwa Salama
GEGamal Esmat
Gamal Esmat

18 September 2019 in BMC Medicine
Verified
Journal Article
Open access
PDF file
NSNick Scott
Nick Scott
DWDavid P. Wilson
David P. Wilson
ATAlexander Thompson
Alexander Thompson
EBEleanor Barnes
Eleanor Barnes
MEManal El-Sayed
Manal El-Sayed
MHMargaret E. Hellard
Margaret E. Hellard
Background: The introduction of highly effective direct-acting antiviral (DAA) therapy for hepatitis C has led to calls to eliminate it as a public health threat through treatment-as-prevention. Recent studies suggest it is possible to develop a vaccine to prevent hepatitis C. Using a mathematical model, we examined the potential impact of a hepatitis C vaccine on the feasibility and cost of achieving the global WHO elimination target of an 80% reduction in incidence by 2030 in the era of DAA treatment. Methods: The model was calibrated to 167 countries and included two population groups (people who inject drugs (PWID) and the general community), features of the care cascade, and the coverage of health systems to deliver services. Projections were made for 2018–2030. Results: The optimal incidence reduction strategy was to implement test and treat programmes among PWID, and in settings with high levels of community transmission undertake screening and treatment of the general population. With a vaccine available, the optimal strategy was to include vaccination within test and treat programmes, in addition to vaccinating adolescents in settings with high levels of community transmission. Of the 167 countries modelled, between 0 and 48 could achieve an 80% reduction in incidence without a vaccine. This increased to 15–113 countries if a 75% efficacious vaccine with a 10-year duration of protection were available. If a vaccination course cost US$200, vaccine use reduced the cost of elimination for 66 countries (40%) by an aggregate of US$7.4 (US$6.6–8.2) billion. For a US$50 per course vaccine, this increased to a US$9.8 (US$8.7–10.8) billion cost reduction across 78 countries (47%). Conclusions: These findings strongly support the case for hepatitis C vaccine development as an urgent public health need, to ensure hepatitis C elimination is achievable and at substantially reduced costs for a majority of countries.